Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6 weeks post-procedure Company's first-in-class technology has demonstrated significant, enduring reduction in pain and improvement in quality of life in ongoing PoC study to date THE WOODLANDS, TX, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve-targeted treatments, today reported financial results for the second quarter fiscal year 2025 ended September 30, 2024 and provi

79% responder rate achieved with zero opioid use and quality of life improvement at 7 days post-procedure Company reaches 60% enrollment with 15 patients1 successfully enrolled; No unexpected complications or procedural-related significant adverse events Clinically meaningful mean of 4.96 or 63% reduction of pain on the VAS pain scale was observed THE WOODLANDS, TX, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced preliminary positive results from the first 15 pa

Access the Virtual Investor "What This Means" Segment here THE WOODLANDS, TX, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it recently participated in a Virtual Investor "What This Means" segment. For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company's recently announced 4-6 week positive follow-up data, from the first five "lead-in" patients in the Company's ongoing proof-of-concept (PoC) human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to

100% of the responder group went to zero opioid use at 4-6 weeks post-procedure Up to 75% of late-stage pancreatic cancer patients are prescribed opioids and data suggests 20% are at risk for abuse and misuse1 Data from the initial "lead-in" cohort show responders experienced a reduction in pain assessed by VAS from 8.0 pre-procedure to 1.33 at 4-6 weeks post-procedure THE WOODLANDS, TX, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve-targeted treatments, today highlighted positive preliminary results from the first five "lead-in" patients in the Company's ongo

THE WOODLANDS, TX, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it will release a Virtual Investor "What This Means" segment on Wednesday, October 30, 2024. For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix will discuss additional findings from the 4-6 week follow-up data from the first five "lead-in" patients in the Company's ongoing proof-of-concept (PoC) human clinical trial. The Virtual Investor "What This Means" segment will be accessible here. About Autonomix Medical, Inc. Autonomix is a medical d

THE WOODLANDS, TX, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will take effect at 11:59 pm (Eastern Time) on October 24, 2024, and the Company's common stock will open for trading on The Nasdaq Capital Market on October 25, 2024 on a post-split basis, under the existing ticker symbol "AMIX" but with a new CUSIP nu

Live webcast fireside chat on Tuesday, October 15th at 2:30 PM ET THE WOODLANDS, TX, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, CEO of Autonomix, will participate in a fireside chat at the 2024 Healthcare Virtual Summit, presented by Maxim Group LLC on October 15, 2024 at 2:30 PM ET. Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presen

THE WOODLANDS, TX, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, addressed Pain Awareness Month and what the Company is doing to address the significant unmet need in pancreatic cancer pain. The CEO Corner segment is now available here. About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innova

THE WOODLANDS, TX, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve-targeted treatments, today announced it has been selected for a featured podium presentation at the 2024 Octane Medical Innovation Forum taking place on October 8-9, 2024 in Irvine, California. The Octane Medical Innovation Forum brings together industry experts, entrepreneurs, investors and thought leaders for two days of learning, networking and innovation on the latest insights and trends in the medical industry. For more information, visit the event website here. As part of the podium presentation

Responders experienced a pain reduction from a pre-procedure pain score of 8 to a pain score of 1.33 at 4-6 weeks post-procedure 60% of patients responded with a mean 6.67 or 83% reduction of pain on the VAS pain scale (from baseline of 8.0 to 1.33) at 4-6 weeks post-procedure 100% of this responder group had clinically meaningful pain relief at 4-6 weeks post-procedure Trial remains on track to complete enrollment by year-end 2024 THE WOODLANDS, TX, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve-targeted treatments, today annou

Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced changes to its executive leadership team to support its next pivotal phase of development. Effective immediately, Brad Hauser has been appointed as President and Chief Executive Officer. Additionally, Lori Bisson, former President and Chief Executive Officer, has been appointed Executive Vice Chairman

Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands THE WOODLANDS, TX, March 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the appointment of Jennifer Cook as its Chief Business Officer. Mrs. Cook is an innovative, cross-functional leader with significant expertise working with early developmental stage companies and building them into fully integrated c

S-1/A - Autonomix Medical, Inc. (0001617867) (Filer)

10-Q - Autonomix Medical, Inc. (0001617867) (Filer)

8-K - Autonomix Medical, Inc. (0001617867) (Filer)

S-1 - Autonomix Medical, Inc. (0001617867) (Filer)

8-K - Autonomix Medical, Inc. (0001617867) (Filer)

8-K - Autonomix Medical, Inc. (0001617867) (Filer)

8-K - Autonomix Medical, Inc. (0001617867) (Filer)

DEF 14A - Autonomix Medical, Inc. (0001617867) (Filer)

PRE 14A - Autonomix Medical, Inc. (0001617867) (Filer)

10-Q - Autonomix Medical, Inc. (0001617867) (Filer)

RF Innovations' Apex 6 Generator aligns with specifications required for Autonomix's ablation system and facilitates ongoing developmentTransaction further reinforces Autonomix's FDA regulatory pathwayTHE WOODLANDS, TX, July 24, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has completed its previously announced transaction with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property to its Apex 6 Radiofrequency Generator. T

Shares of Selective Insurance Group, Inc. (NASDAQ:SIGI) fell sharply during Friday's session following weak quarterly results. Selective Insurance reported quarterly losses of $1.10 per share which missed the analyst consensus estimate of $1.49 per share. The company reported quarterly sales of $1.196 billion which missed the analyst consensus estimate of $1.204 billion, according to data from Benzinga Pro. Selective Insurance Group shares dipped 14.8% to $85.40 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Augmedix, Inc. (NASDAQ:AUGX) shares jumped 148.8% to $2.28 after the company announced it will be acquired by Commure. 60 Degrees Pha

Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) fell sharply during Wednesday's session after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for voluntary liquidation. ASLAN Pharmaceuticals shares dipped 38.7% to $0.68 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Aptevo Therapeutics Inc. (NASDAQ:APVO) shares climbed 84% to $0.6073 after surging around 10% on Tuesday. Aptevo Therapeutics recently announced closing of $2.75 million offering. Shimmick Corporation (NASDAQ:SHIM) shares climbed 49% to $3.0173 after the company received a $27.6 million subcontract for the Sunol Valley Water Trea

Shares of The Charles Schwab Corporation (NYSE:SCHW) fell sharply during Tuesday's session following second-quarter results. Charles Schwab said adjusted net income declined 2% Y/Y to $1.465 billion. Adjusted EPS fell 3% Y/Y to 73 cents, beating the consensus of 72 cents, according to data from Benzinga Pro. Charles Schwab shares dipped 7.5% to $69.42 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Yoshitsu Co., Ltd (NASDAQ:TKLF) jumped 109% to $0.6437 after the company reported a year-over-year increase in FY24 financial results. Silo Pharma, Inc. (NASDAQ:SILO) shares climbed 95.4% to $2.12 after the company obtained an exclusive global l

U.S. stocks traded higher this morning, with the Dow Jones index rising more than 400 points on Tuesday. Following the market opening Tuesday, the Dow traded up 1% to 40,614.31 while the NASDAQ rose 0.14% to 18,498.00. The S&P 500 also rose, gaining, 0.33% to 5,649.84. Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Industrials Stocks Delivering High-Dividend Yields Leading and Lagging SectorsIndustrials shares jumped by 1.2% on Tuesday. In trading on Tuesday, energy shares fell by 0.6%. Top Headline U.S. retail sales came in flat month-over-month for June compared to a revised 0.3% gain in the previous period. Equities Trading UP                     

Shares of Match Group, Inc. (NASDAQ:MTCH) rose sharply in today's pre-market trading. Starboard Value has taken a keen interest in Match Group. The hedge fund has accumulated a stake of over 6.5% in the online dating company and is advocating for a potential sale if the company's performance does not improve, The Wall Street Journal reported on Monday, citing people familiar with the matter. Match Group shares jumped 8% to $34.56 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Conduit Pharmaceuticals Inc. (NASDAQ:CDT) gained 89.8% to $0.4556 in pre-market trading after declining over 8% on Monday. Meiwu Technology Company Limited (NA

Autonomix Medical Inc (NASDAQ:AMIX) blasted higher Monday after the company entered into an agreement with RF Innovations to license intellectual property for its Apex 6 Radiofrequency Generator. What To Know: Autonomix said the transaction, for 250,000 shares of common stock, grants Autonomix a perpetual non-exclusive worldwide and royalty-free license of the Apex 6 Generator intellectual property. The Apex 6 Radiofrequency Generator is an FDA-cleared ablation technology designed to lesion neural tissue for pain management in the peripheral nervous system.  The transaction is expected to close before the end of July, and Autonomix said it plans to utilize the technology in its str

U.S. stocks traded higher toward the end of trading, with the Dow Jones index rising more than 150 points on Monday. The Dow traded up 0.44% to 40,178.06 while the NASDAQ rose 0.29% to 18,451.73. The S&P 500 also rose, gaining, 0.25% to 5,629.59. Check This Out: Over $18M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying Leading and Lagging SectorsEnergy shares jumped by 2% on Monday. In trading on Monday, utilities shares fell by 1.8%. Top Headline Goldman Sachs Group Inc. (NYSE:GS) reported better-than-expected results for its second quarter. Goldman posted revenue of $12.730 billion for the second quarter, beating the consensus of $12.456 billion.

Shares of SolarEdge Technologies, Inc. (NASDAQ:SEDG) fell sharply during Monday's session after the company announced a workforce reduction. SolarEdge disclosed a decision to lay off 400 employees. The company stated that 200 of these job cuts are in Israel. The action involves reducing headcount and discretionary spending across all departments. SolarEdge Technologies shares dipped 12.2% to $27.77 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Autonomix Medical, Inc. (NASDAQ:AMIX) shares climbed 148% to $1.4850 after the company entered into an agreement with RF Innovations to license intellectual property for its Apex 6 Radiofrequency Gener

U.S. stocks traded higher midway through trading, with the Nasdaq Composite rising more than 200 points on Monday. The Dow traded up 0.73% to 40,291.69 while the NASDAQ rose 1.16% to 18,611.47. The S&P 500 also rose, gaining, 0.81% to 5,660.67. Check This Out: Over $18M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying Leading and Lagging SectorsEnergy shares jumped by 1.6% on Monday. In trading on Monday, utilities shares fell by 2.1%. Top Headline The NY Empire State Manufacturing Index fell to a reading of -6.6 in July, compared to market estimates of -6. Equities Trading UP                        Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) sh